EYLEA achieves primary endpoint in BRVO Study

Regeneron Pharmaceuticals achieved positive results for EYLEA (aflibercept) Injection from the Phase III VIBRANT study in patients with Macular Edema following Branch Retinal Vein Occlusion (BRVO). In the trial, 53% of patients who received EYLEA 2 milligram every four weeks gained at least 15 letters in vision from baseline at week 24, the primary endpoint of the study, compared to 27% of patients who received laser, a standard-of-care treatment.
 
The incidence of serious adverse events (SAE) was 9.9% in the EYLEA group and 9.8% in the laser group. The most common ocular adverse events in the EYLEA treated patients were conjunctival hemorrhage and eye pain.  
 
EYLEA is currently approved for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD) and Macular Edema following Central Retinal Vein Occlusion (CRVO).